Summary Age could influence the prognosis of multiple myeloma patients treated with conventional chemotherapy. Between January 1987 and March 1990, 341 consecutive previously untreated patients with multiple myeloma received chemotherapy within the prospective, multicentre, randomized Protocol MM87. Survival was evaluated in patients aged > or < 66 years (the median age for the whole series) and in a subgroup of patients aged < 55 years. These groups were similar for main clinical characteristics, including results of cytostatic treatment. As of May 1996, 271 (79%) of the 341 patients had died, and median follow-up of the 70 (21%) living patients was 82 months. Overall, younger patients survived longer than older ones. In fact, in patients > and < 66 years, median survival was 31 and 44 months (P < 0.00095) and the percentage of patients surviving over 72 months was 17% and 32% (P = 0.0018) respectively; in patients < 55 years, these figures were 57 months and 35% respectively (P = 0.02 and 0.01, with respect to patients aged . 55 years). In all groups, about 50% of the patients surviving over 72 months had stage I disease. For multiple myeloma patients treated with chemotherapy, survival is favourably affected by relatively young age and early stage of disease.
A typical series of patients with multiple myeloma (MM) has a median age of about 65 years and survive a median time of about 3 years when treated with conventional chemotherapy (CT) (Alexianan et al, 1969; Sporn et al, 1986 , Osteborg et al, 1989 Riccardi et al, 1994) .
Age could influence survival, but little attention has been paid to this topic. In some studies (Kelly et al, 1988; Cavo et al, 1989) , younger patients treated with CT tend to survive longer than older ones, by univariate analysis. The relevance of age tends to be lower when this parameter is included as a continuous variable into multiple regression analysis (Grignani et al, 1995) . The actual more relevant prognostic role for relatively young age in MM is that it is a prerequisite for administering allogeneic or autologous bone marrow transplantation (BMT) (Fermand et al, 1993; Jagannath et al, 1993; Bjorkstrand et al, 1994; Cunningham et al, 1994; Gharton et al, 1995; Harosseau et al, 1995 Harosseau et al, , 1996 Attal et al, 1996; Bensiger et al, 1996; Marit et al, 1996; Vesole et al, 1996) .
We examined the definitive survival by age in 341 consecutive previously untreated MM patients from the prospective, multicentre, randomized Protocol MM87 started in January 1987 and closed in March 1990. The survival of patients aged less than 66 years, i.e. the median age for the whole series, is compared with the survival of age-matched patients treated with bone marrow transplantation (BMT) in a literature series.
MATERIALS AND METHODS
Between January 1987 and March 1990, 341 patients with previously untreated MM entered the prospective, multicentre, randomized Protocol MM87 (Riccardi et al, 1994 ).
Summary of Protocol MM87
Patients were staged (Durie and Salmon, 1975) and randomized for both induction and maintenance therapy. A less or more aggressive first-line induction policy was adopted for stage I (melphalan and prednisone, MPH-P, delayed until disease progression vs MPH-P given immediately after diagnosis) and stage III (MPH-P vs peptichemio, vincristine and prednisone, PTC-VCR-P) patients. Patients with stage II disease were uniformly treated with MPH-P. Response was according to slightly modified clinical criteria adopted by the SECSG (Cohen et al, 1979) , as detailed elsewhere (Riccardi et al, 1994) . Response was evaluated after six courses of MPH-P or four courses of PTC-VCR-P.
Within each stage, patients who had complete or partial response were randomized between receiving additional courses of induction therapy until maximum reduction in the monoclonal component (MC) (i.e. the plateau phase) was achieved (Riccardi et al, 1994) and then stopping all cytostatics until relapse or continuing therapy indefinitely until relapse, as a maintenance.
Patients who were resistant with one regimen or progressed or relapsed during maintenance with this regimen were crossed to the other regimen, as a second-line therapy. Hence, patients who were originally treated with MPH-P for induction were treated with PTC-VCR-P and patients originally treated with PTC-VCR-P were treated with MPH-P. Patients who achieved response on second-line treatment continued on maintenance therapy with the same drugs until relapse.
Patients who were primarily resistant to or relapsed after a response to first-and second-line therapies of Protocol MM87 were randomized between epirubicin and cyclophosphamide, both combined with prednisone and a2b-IFN (Brugnatelli et al, 1996) .
Data collection
Just after the first randomization, a protocol entrance form had to be completed (specifying data that validated the diagnosis and the stage) and a photocopy sent to the coordinating centre. Every 6 months the entrance form was updated, and cooperative group meetings were held regularly in Pavia. Main clinical results of the MM87 Protocol have been detailed from data analysis collected in May 1993, when 59% of the patients had died (Riccardi et al, 1994) . In May 1996, when 79% of the patients had died, a reanalysis of survival and of causes of deaths was performed. Medical form records or a death certificate-based search were used. (Ballester et al, 1993; Gharton et al, 1995 Survival curves were obtained using the method of Kaplan and Meier (1958) . Patients were considered to be alive if their last evaluation was within 6 months, and death was not documented. All deaths were considered as events regardless of their cause. Differences in overall survival between groups were analysed using the log-rank test, taking censored data into account.
RESULTS
The results of this study are reported in Tables 1-4 and Figures 1-4 . At the time of this reanalysis (May 1996), 271 (79%) of the 341 patients who entered the Protocol MM87 had died and the median follow-up of the 70 (21%) living patients was 82 months.
Patients characteristics
The series of patients > and < 66 years and less than 55 years were similar for main clinical characteristics (Table 1) . There was no indolent and / or smouldering MM.
Median survival of patients aged > or < 66 years Ten years after starting the MM87 protocol, prognosis was worse for patients > 66 years than for patients < 66 years. In fact, patients > and < 66 years survived a median of 31 and 44 months respectively (P = 0.00095) (Figure 1) , with first-response duration not significantly different in the two groups [25.1 (1-57) months and 22.8 (1-60) months]. Survivors over 6 years were 17% and 32% among patients > and < 66 years respectively (P = 0.0018) (Figure 1) .
For stage I patients aged > 66 and < 66 years, median survival was 50 months and not reached at 100 months respectively. The 6-year survival was 39% and 65% respectively (P = 0.0089) ( Figure  2 ). For stage II and III patients aged > or < 66 years, median survival was 27 and 36 months respectively (P = 0.017). The 6-year survival was 11% and 22% respectively (P = 0.14) (Figure 3) . For complete or partial responders with stage II and III disease aged > or < 66 years (54 and 58 patients respectively), median survival was 38 and 50 months respectively (P = 0.017). The 6-year survival was 18% and 26% respectively (P = 0.3) ( Table 3) .
Median survival of patients aged less than 55 years
The subgroup of 49 patients < 55 years survived a median of 57 months (P = 0.022 with respect to survival of patients 55 years) (Figure 4 ) and 35% of them survived more than 6 years (P = 0.012 with respect to survival of patients 2 55 years).
Median survival was not reached at 100 months for 13 stage I patients; it was 73 months for 14 stage II patients and 38 months for 22 stage III patients. The 6-year survival was 54% (7 of 13 patients) for stage I, 50% (7 of 14 patients) for stage II and 14% (3 of 22 patients) for stage III patients. aThese patients represent a subset of the whole series and are also included in the group of patients < 66 years.
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Causes of death
Causes of death could be ascertained for 175 of 271 patients (Table  4) . There were no differences in the percentage distribution of causes of death that were related or unrelated to MM among the three groups aged > 66 years, < 66 years and < 55 years.
DISCUSSION
The reanalysis of Protocol MM87 indicates that relatively young age is a favourable prognostic factor in MM treated with CT, independent of the type of initial cytostatic treatment (MPH-P or PTC-VCR-P). In fact, patients aged more than 66 years (median age of this series) and patients aged 66 years or less survived for a median time of 31 and 44 months respecti-vely; among the two groups, patients who survived over 72 months were 17% and 32% respectively. Prognosis was even better in the subgroup of patients aged less than 55 years, who survived a median time of 57 months and the 35% of whom survived over 72 months. A possible cause for better survival of younger patients could be that these patients are better able to tolerate subsequent treatments (as third-and fourthline chemotherapies), possibly because of a better-maintained performance status and a reduced frequency of intercurrent illness.
The comparison of survival of patients aged < 66 years treated with CT with that of age-matched groups of patients treated with bone marrow transplantation (BMT) is feasible to a limited degree. A major cause for this limitation is that the follow-up of most BMT series is relatively short (4 years or, more often, 3 years), so that putative end results for evaluable patients are actually expressed as 'probability' or 'projection' of being long-term alive or disease free. In contrast, data from our series are substantially conclusive, as patients were recruited between 1987 and 1990 and survival is updated in 1996. Another well-known difficulty in (1996); Vesole et al (1996) . bPresent series.
comparing CT and BMT series is that early BMT-related mortality accounts for a variable percentage (from 2% to 25%) of early deaths, so that median survival tends to be lowered in transplanted MM. Finally, the minor drawbacks are the partly different composition of the series and the fact that reports from BMT procedures exclude from evaluation a different number of patients, because of different reasons.
With these limitations in mind, Tables 5 and 6 attempt this comparison. The tables are compiled using median and 4-year survival, as the commonest data can be found in most BMT series (Fermand et al, 1993; Jagannath et al, 1993; Bjorkstrand et al, 1994; Cunningham et al, 1994; Harosseau et al, 1995; Attal et al, 1996; Bensiger et al, 1996; Marit et al, 1996; Vesole et al, 1996) and are useful for comparison with our series (Table 3) . Additionally, for literature series, data on 4-year survival given by the authors (as a % of single series) have also been cumulated by calculating the actual percentage of patients of all series surviving 4 years.
Evaluating all MM stages (I to III) aged < 66 years (Table 5) , the 4-year survival is 46% in our series and 40% (32-63%) in five Attal et al (1996); Marit et al (1996) . bPresent series; Attal et al (1996) . cPresent series; Blade et al (1996) .
autologous BMT series with lower median age (Jagannath et al, 1993; Bjorkstrand et al, 1994; Cunningham et al, 1994; Bensiger et al, 1996; Vesole et al, 1996) . Median survival was 44 months in our series and 28-41 months in autologous BMT series (Jagannath et al, 1993; Bjorkstrand et al, 1994; Besinger et al, 1996; Vesole et al, 1996) . In the only published series in which patients aged less than 55 years were treated with allogeneic BMT (Gahrton et al, 1995) , median survival was 17 months and 4-year survival was 34%. The corresponding figures for our < 55 years patients are 57 months and 46% (Figure 4) . Some of the autologous BMT series in the literature (Fermand et al, 1993; Harousseau et al, 1995; Attal et al, 1996; Marit et al, 1996) exclude stage I patients from transplantation procedures because of the intrinsic good prognosis of these patients. Actually, in our series also, early disease was a contributing factor for long survival. In fact, the 46-50% of patients surviving over 6 years were stage I MM, compared with the 22-26% with stage I disease included in the whole series. With these exclusions, stage II and III disease accounts for 71-89% (the weighted mean value is 75%) of patients in the autologous BMT series and for 65% of patients in our series.
The 4-year survival for transplanted stage II and III is 58% (55-65%) (Fermand et al, 1993; Harousseau et al, 1995; Attal et al, 1996; Marit et al, 1996) and median survival ranges from 46 to 59 months (Table 6 ). Actually, the 58% 4-year survival calculated in the autologous BMT series is optimistic, as the 61% and 65% 4-year survival figures projected in two (Attal et al, 1996; Marit et al, 1996) of these series need to be confirmed with a longer follow-up than the actual follow-up of 41 and 27 months respectively (Atkis, 1996; Oivanen and Palva, 1996) .
With CT, the 4-year survival for all stage II and Ill patients was lower, i.e. 36% (35-37%) in our and in another literature series (Attal et al, 1996) and median survival was 36 and 37 months. However, results are improved when CT-responding patients are considered, who are often the true candidates for transplantation (Blade et al, 1996) . In fact, the 4-year survival for responsive stage II-III patients was 53% (50-56%) (Blade et al, 1996 ; present series) and median survival was 50 months and about 60 months respectively. However, the fact that the age of conventionally treated patients is higher than the age of transplanted patients must still be accounted for (Table 6) .
Summarizing these data, there is no apparent advantage in treating all relatively young MM patients with BMT rather than with CT (Table 5) , because 4-year survival is similar and median survival is shorter with BMT than with CT. For stage LI-III MM (Table 6 ), autologous BMT could offer some advantage over CT, because median survival is similar with the two procedures and 4-year survival is superior with BMT. However, the BMT advantage actually disappears when comparing the prognosis of chemotherapy-responsive patients (who are the usual candidates to BMT) with that of transplanted stage II-III patients.
Two obvious points need to be emphasized. First, a longer follow-up of BMT series is needed for comparing definitive BMT with definitive CT survival data, such as those originating from the MM87 Protocol. Second, prospective randomized studies, with adequate follow-up, could evaluate the relative advantage of treating relatively young MM patients with CT or with BMT.
